|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ottaviani G and Jaffe N: The etiology of
osteosarcoma. Cancer Treat Res. 152:15–32. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kager L, Zoubek A, Pötschger U, Kastner U,
Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M,
Winkelmann W, et al Cooperative German-Austrian-Swiss Osteosarcoma
Study Group, : Primary metastatic osteosarcoma: Presentation and
outcome of patients treated on neoadjuvant Cooperative Osteosarcoma
Study Group protocols. J Clin Oncol. 21:2011–2018. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Briccoli A, Rocca M, Salone M, Guzzardella
GA, Balladelli A and Bacci G: High grade osteosarcoma of the
extremities metastatic to the lung: Long-term results in 323
patients treated combining surgery and chemotherapy, 1985–2005.
Surg Oncol. 19:193–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
6
|
Griffiths-Jones S, Grocock RJ, van Dongen
S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets
and gene nomenclature. Nucleic Acids Res. 34:D140–D144. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang
X and Wang L: Down-regulation of miR-183 promotes migration and
invasion of osteosarcoma by targeting Ezrin. Am J Pathol.
180:2440–2451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cui SQ and Wang H: MicroRNA-144 inhibits
the proliferation, apoptosis, invasion, and migration of
osteosarcoma cell line F5M2. Tumour Biol. 36:6949–6958. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Won KY, Kim YW, Kim HS, Lee SK, Jung WW
and Park YK: MicroRNA-199b-5p is involved in the Notch signaling
pathway in osteosarcoma. Hum Pathol. 44:1648–1655. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang G, Nishimoto K, Zhou Z, Hughes D and
Kleinerman ES: miR-20a encoded by the miR-17-92 cluster increases
the metastatic potential of osteosarcoma cells by regulating Fas
expression. Cancer Res. 72:908–916. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Y, Xu J, Jiang M, Ni L, Chen Y and
Ling Y: Association between functional PSMD10 Rs111638916 variant
regulated by MiR-505 and gastric cancer risk in a Chinese
population. Cell Physiol Biochem. 37:1010–1017. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schultz NA, Dehlendorff C, Jensen BV,
Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE,
Yilmaz M, Holländer NH, et al: MicroRNA biomarkers in whole blood
for detection of pancreatic cancer. JAMA. 311:392–404. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ninomiya M, Kondo Y, Funayama R, Nagashima
T, Kogure T, Kakazu E, Kimura O, Ueno Y, Nakayama K and Shimosegawa
T: Distinct microRNAs expression profile in primary biliary
cirrhosis and evaluation of miR 505–3p and miR197-3p as novel
biomarkers. PLoS One. 8:e660862013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Erlandsson Harris H and Andersson U:
Mini-review: The nuclear protein HMGB1 as a proinflammatory
mediator. Eur J Immunol. 34:1503–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Charoonpatrapong K, Shah R, Robling AG,
Alvarez M, Clapp DW, Chen S, Kopp RP, Pavalko FM, Yu J and Bidwell
JP: HMGB1 expression and release by bone cells. J Cell Physiol.
207:480–490. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang D, Kang R, Zeh HJ III and Lotze MT:
High-mobility group box 1 and cancer. Biochim Biophys Acta.
1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meyers PA, Schwartz CL, Krailo MD, Healey
JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM,
Harris M, et al Childrens Oncology Group, : Osteosarcoma: The
addition of muramyl tripeptide to chemotherapy improves overall
survival - a report from the Childrens Oncology Group. J Clin
Oncol. 26:633–638. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grignani G, Palmerini E, Dileo P, Asaftei
SD, DAmbrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F,
Casali PG, et al: A phase II trial of sorafenib in relapsed and
unresectable high-grade osteosarcoma after failure of standard
multimodal therapy: an Italian Sarcoma Group study. Ann Oncol.
23:508–516. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goorin AM, Schwartzentruber DJ, Devidas M,
Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE and Link MP;
Pediatric Oncology Group, : Presurgical chemotherapy compared with
immediate surgery and adjuvant chemotherapy for nonmetastatic
osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin
Oncol. 21:1574–1580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nugent M: microRNA and Bone Cancer. Adv
Exp Med Biol. 889:201–230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Osaki M, Takeshita F, Sugimoto Y, Kosaka
N, Yamamoto Y, Yoshioka Y, Kobayashi E, Yamada T, Kawai A, Inoue T,
et al: MicroRNA-143 regulates human osteosarcoma metastasis by
regulating matrix metalloprotease-13 expression. Mol Ther.
19:1123–1130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao H, Li M, Li L, Yang X, Lan G and
Zhang Y: MiR-133b is down-regulated in human osteosarcoma and
inhibits osteosarcoma cells proliferation, migration and invasion,
and promotes apoptosis. PLoS One. 8:e835712013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao J, Chen F, Zhou Q, Pan W, Wang X, Xu
J, Ni L and Yang H: Aberrant expression of microRNA-99a and its
target gene mTOR associated with malignant progression and poor
prognosis in patients with osteosarcoma. Onco Targets Ther.
9:1589–1597. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamamoto Y, Yoshioka Y, Minoura K,
Takahashi RU, Takeshita F, Taya T, Horii R, Fukuoka Y, Kato T,
Kosaka N, et al: An integrative genomic analysis revealed the
relevance of microRNA and gene expression for drug-resistance in
human breast cancer cells. Mol Cancer. 10:1352011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen S, Sun KX, Liu BL, Zong ZH and Zhao
Y: MicroRNA-505 functions as a tumor suppressor in endometrial
cancer by targeting TGF-α. Mol Cancer. 15:112016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu L, Qiu C, Li D, Bai G, Liang J and Yang
Q: MicroRNA-505 suppresses proliferation and invasion in hepatoma
cells by directly targeting high-mobility group box 1. Life Sci.
157:12–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Daw NC, Billups CA, Rodriguez-Galindo C,
McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD and Meyer WH:
Metastatic osteosarcoma. Cancer. 106:403–412. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xiao J, Ding Y, Huang J, Li Q, Liu Y, Ni
W, Zhang Y, Zhu Y, Chen L and Chen B: The association of HMGB1 gene
with the prognosis of HCC. PLoS One. 9:e890972014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scaffidi P, Misteli T and Bianchi ME:
Release of chromatin protein HMGB1 by necrotic cells triggers
inflammation. Nature. 418:191–195. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jube S, Rivera ZS, Bianchi ME, Powers A,
Wang E, Pagano I, Pass HI, Gaudino G, Carbone M and Yang H: Cancer
cell secretion of the DAMP protein HMGB1 supports progression in
malignant mesothelioma. Cancer Res. 72:3290–3301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xia Q, Xu J, Chen H, Gao Y, Gong F, Hu L
and Yang L: Association between an elevated level of HMGB1 and
non-small-cell lung cancer: A meta-analysis and literature review.
Onco Targets Ther. 9:3917–3923. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ito I, Fukazawa J and Yoshida M:
Post-translational methylation of high mobility group box 1 (HMGB1)
causes its cytoplasmic localization in neutrophils. J Biol Chem.
282:16336–16344. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cottone L, Capobianco A, Gualteroni C,
Perrotta C, Bianchi ME, Rovere-Querini P and Manfredi AA:
5-Fluorouracil causes leukocytes attraction in the peritoneal
cavity by activating autophagy and HMGB1 release in colon carcinoma
cells. Int J Cancer. 136:1381–1389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
He J, Zhang P, Li Q, Zhou D and Liu P:
Expression of high mobility group box 1 protein predicts a poorer
prognosis for patients with osteosarcoma. Oncol Lett. 11:293–298.
2016.PubMed/NCBI
|
|
37
|
Yang J, Shah R, Robling AG, Templeton E,
Yang H, Tracey KJ and Bidwell JP: HMGB1 is a bone-active cytokine.
J Cell Physiol. 214:730–739. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R,
Vernon P, Cao L and Tang D: HMGB1 promotes drug resistance in
osteosarcoma. Cancer Res. 72:230–238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huang J, Liu K, Yu Y, Xie M, Kang R,
Vernon P, Cao L, Tang D and Ni J: Targeting HMGB1-mediated
autophagy as a novel therapeutic strategy for osteosarcoma.
Autophagy. 8:275–277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guo S, Bai R, Liu W, Zhao A, Zhao Z, Wang
Y, Wang Y, Zhao W and Wang W: miR-22 inhibits osteosarcoma cell
proliferation and migration by targeting HMGB1 and inhibiting
HMGB1-mediated autophagy. Tumour Biol. 35:7025–7034. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mari E, Zicari A, Fico F, Massimi I,
Martina L and Mardente S: Action of HMGB1 on miR-221/222 cluster in
neuroblastoma cell lines. Oncol Lett. 12:2133–2138. 2016.PubMed/NCBI
|
